Supporting CD44’s role in glioma aggressiveness, CD44+/+ tumors were the most aggressive, CD44−/− tumors were the least aggressive, and CD44−/+ tumors were somewhere in between. This evidence concerns the gene CD44 and central nervous system cancer.